United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.34% | 11.68% | 14.47% | 16.15% | 15.25% |
| Total Depreciation and Amortization | 14.36% | 18.07% | 24.06% | 31.30% | 40.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 340.15% | 344.96% | -2.15% | 12.64% | 37.31% |
| Change in Net Operating Assets | -508.79% | -2,830.77% | 165.94% | 54.58% | 122.73% |
| Cash from Operations | 10.73% | 17.64% | 36.92% | 24.03% | 44.11% |
| Capital Expenditure | -92.94% | -111.16% | -82.10% | -31.88% | -24.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 552.66% | -104.64% | -101.38% | -157.41% | -136.07% |
| Cash from Investing | 173.96% | -232.14% | -176.72% | -282.99% | -303.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -25.00% | -50.00% | -133.33% | -100.00% |
| Issuance of Common Stock | 73.80% | 14.37% | -22.64% | -10.41% | 57.74% |
| Repurchase of Common Stock | -15,829.19% | -0.93% | -0.92% | 97.90% | 98.41% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -325.93% | -325.93% | -325.93% | 100.00% |
| Cash from Financing | -805.42% | 8.35% | -3.94% | 64.10% | 75.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.65% | -128.62% | -147.92% | -17.68% | 636.82% |